Literature DB >> 1777359

Abnormal patterns of DNA methylation in human neoplasia: potential consequences for tumor progression.

S B Baylin1, M Makos, J J Wu, R W Yen, A de Bustros, P Vertino, B D Nelkin.   

Abstract

An imbalance of DNA methylation, involving widespread hypomethylation, regional hypermethylation and increased cellular capacity for methylation, is characteristic of human neoplasia. This imbalance begins in preneoplastic cells and becomes more extensive throughout subsequent stages of tumor progression. In normal cells, a primary function of DNA methylation may be to modulate compartmentalization of DNA to ensure that regional areas of transcriptionally active chromatin replicate earlier than the bulk transcriptionally inactive chromatin. We argue here that the altered methylation patterns observed during tumor progression, especially regional hypermethylation, may mark--or even help to establish--abnormalities of chromatin organization. In turn, these changes in chromatin structure may, through direct transcriptional inactivation of genes, predisposition to mutations, and allelic deletions, mediate the progressive losses of gene expression associated with tumor development.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1777359

Source DB:  PubMed          Journal:  Cancer Cells        ISSN: 1042-2196


  52 in total

1.  Evidence for clonal origin of neoplastic neuronal and glial cells in gangliogliomas.

Authors:  J J Zhu; S P Leon; R D Folkerth; S Z Guo; J K Wu; P M Black
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

2.  Mitochondrial regulation of cancer associated nuclear DNA methylation.

Authors:  Cheng-hui Xie; Akihiro Naito; Takatsugu Mizumachi; Teresa T Evans; Michael G Douglas; Craig A Cooney; Chun-Yang Fan; Masahiro Higuchi
Journal:  Biochem Biophys Res Commun       Date:  2007-10-16       Impact factor: 3.575

3.  Concurrent replication and methylation at mammalian origins of replication.

Authors:  F D Araujo; J D Knox; M Szyf; G B Price; M Zannis-Hadjopoulos
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

4.  Isolation and characterization of the cDNA encoding human DNA methyltransferase.

Authors:  R W Yen; P M Vertino; B D Nelkin; J J Yu; W el-Deiry; A Cumaraswamy; G G Lennon; B J Trask; P Celano; S B Baylin
Journal:  Nucleic Acids Res       Date:  1992-05-11       Impact factor: 16.971

5.  Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide.

Authors:  S Ramchandani; A R MacLeod; M Pinard; E von Hofe; M Szyf
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

6.  DNA methyltransferase contributes to delayed ischemic brain injury.

Authors:  M Endres; A Meisel; D Biniszkiewicz; S Namura; K Prass; K Ruscher; A Lipski; R Jaenisch; M A Moskowitz; U Dirnagl
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

Review 7.  Spontaneous regression of pancreatic cancer: real or a misdiagnosis?

Authors:  Marta Herreros-Villanueva; Elizabeth Hijona; Angel Cosme; Luis Bujanda
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

8.  Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFN-gamma) promoter and subsequent downregulation of IFN-gamma production.

Authors:  J A Mikovits; H A Young; P Vertino; J P Issa; P M Pitha; S Turcoski-Corrales; D D Taub; C L Petrow; S B Baylin; F W Ruscetti
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

9.  Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas.

Authors:  K Yoshiura; Y Kanai; A Ochiai; Y Shimoyama; T Sugimura; S Hirohashi
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

10.  Oxidative stress and DNA methylation in prostate cancer.

Authors:  Krishna Vanaja Donkena; Charles Y F Young; Donald J Tindall
Journal:  Obstet Gynecol Int       Date:  2010-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.